New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
08:21 EDTPKI, DDXS, WAT, PACB, AFFX, SQNM, FLDMMaxim recommends life science tools, diagnostics ahead of earnings
Maxim expects 2014 to be a "great year" for life science tools and diagnostics stocks and recommends buying Affymetrix (AFFX), diaDexus (DDXS), Fluidigm (FLDM), Pacific Biosciences (PACB), PerkinElmer (PKI), Sequenom (SQNM) and Waters (WAT) ahead of the Q4 results. Maxim has a preference for Pacific Biosciences, PerkinElmer and Waters. The firm raised its price target for Fluidigm to $52 from $42 and for Pacific Biosciences to $9 from $8.
News For AFFX;DDXS;FLDM;PACB;PKI;SQNM;WAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
16:33 EDTSQNMSequenom to consolidate Michigan and North Carolina facilities
Subscribe for More Information
May 22, 2015
10:35 EDTSQNMSequenom genetic test false positive highlighted in NBC Nightly News report
Recent studies have "cast doubt" on the reliability of pre-natal genetic tests such as Sequenom's MaterniT21 test, according to a report aired by NBC Nightly News. Reference Link
May 18, 2015
07:22 EDTPKI, WATUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link
06:38 EDTFLDMFluidigm shares offer attractive entry point, says Leerink
Leerink believes the current share of Fluidigm represents an attractive entry point ahead of the company's new product launches. The firm thinks Fluidigm is well positioned to benefit from the growth in single cell analysis. It keeps an Outperform rating on the name with a $45 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use